Gnosis gets FDA no objection GRAS for non-animal chondroitin

- Last updated on GMT

© iStock/Wavebreakmedia
© iStock/Wavebreakmedia

Related tags: Chondroitin sulfate

The US Food and Drug Administration (FDA) has issued a letter of no objection for the GRAS (Generally Recognized as Safe) status of Gnosis S.p.A.’s Mythocondro-branded non-animal chondroitin sulfate for use in foods and beverages.

Chondroitin sulphate has been claimed to help relieve joint pain and conditions such as osteoarthritis, with a review by the Cochrane Collaboration​ last year confirming its efficacy.

But its animal-derived nature has caused its safety and purity to be questioned​.

Gnosis launched Mythocondro at Supply Side West 2016 in Las Vegas.

The company uses a fermentation process to produce its CS product, which it says makes the product consistent.

The notice, which can be accessed here​, is for levels of the ingredient ranging from 50 to 200 milligrams per serving in beverage and beverage bases, milk and milk products, and chewing gum.

“With this new important achievement the US market opens its doors to Mythocondro, also suitable for people with dietary restrictions related to religious and animal supply issues,”​ said the company in a press release. “Mythocondro is under registration in several countries; in Europe the Novel Food Approval by EFSA is ongoing.”

Related topics: Suppliers, Bone & joint health

Related news

Related products

show more

Sulfur: The Forgotten Nutrient

Sulfur: The Forgotten Nutrient

Bergstrom Nutrition | 26-Feb-2020 | Technical / White Paper

OptiMSM® is a proven source of bio-available sulfur, the third most abundant mineral in the human body. Overlooking its role may come at the expense of...

Gemini Pharmaceuticals and Transparency

Gemini Pharmaceuticals and Transparency

Gemini Pharmaceuticals | 01-Sep-2019 | Application Note

The industry has shown improvement in its transparency in the past 5 years. Per the regulations, a Brand Owner is 100% responsible for the quality of...

Clinically Proven Omega-3 formula for Joint Health

Clinically Proven Omega-3 formula for Joint Health

KD Pharma Group | 01-Sep-2019 | Data Sheet

KD Nutra is pleased to announce the completion of a clinical trial for its Move3™ omega-3 joint formulation. The trial has shown that Move3™ has a significant...

Related suppliers

Follow us

Featured Events

View more


View more